Abstract
The Serratia marcescens enzyme (SME) is a chromosomally encoded carbapenemase with no known optimal treatment. Various β-lactam/β-lactamase inhibitors and comparators were evaluated against 8 SME producers via broth microdilution. Four isolates were subsequently tested via time-kill analyses. All isolates were resistant to imipenem, imipenem-relebactam, and meropenem but susceptible to ceftazidime, ceftazidime-avibactam, and meropenem-vaborbactam. Ceftazidime, imipenem-relebactam, and meropenem-vaborbactam were bactericidal against 3, 0, and 4 isolates, respectively. Meropenem-vaborbactam may be a potential option for severe SME-producing infections.
Keywords:
SME; Serratia marcescens; carbapenem-resistant Enterobacteriaceae; imipenem-relebactam; meropenem-vaborbactam.
Copyright © 2020 American Society for Microbiology.
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Azabicyclo Compounds / pharmacology
-
Bacterial Proteins / genetics*
-
Boronic Acids / pharmacology
-
Carbapenem-Resistant Enterobacteriaceae / drug effects*
-
Ceftazidime / pharmacology
-
Drug Combinations
-
Drug Resistance, Multiple, Bacterial / drug effects
-
Drug Resistance, Multiple, Bacterial / genetics
-
Humans
-
Imipenem / pharmacology
-
Meropenem / pharmacology
-
Microbial Sensitivity Tests
-
Serratia Infections / microbiology
-
Serratia marcescens / drug effects*
-
Serratia marcescens / genetics
-
Serratia marcescens / isolation & purification
-
beta-Lactamase Inhibitors / pharmacology
-
beta-Lactamases / genetics*
Substances
-
Anti-Bacterial Agents
-
Azabicyclo Compounds
-
Bacterial Proteins
-
Boronic Acids
-
Drug Combinations
-
avibactam, ceftazidime drug combination
-
beta-Lactamase Inhibitors
-
vaborbactam
-
Imipenem
-
Ceftazidime
-
beta-Lactamases
-
carbapenemase
-
Meropenem
-
relebactam